NASDAQ: RYTMRhythm Pharmaceuticals Inc Stock
$63.19+0.46 (+0.73%)
Updated Jun 30, 2025
RYTM Price
$63.19
Fair Value Price
N/A
Market Cap
$4.02B
52 Week Low
$40.46
52 Week High
$69.89
P/E
-22.49x
P/B
212.18x
P/S
24.41x
PEG
N/A
Dividend Yield
N/A
Revenue
$136.86M
Earnings
-$168.69M
Gross Margin
89.6%
Operating Margin
-108.04%
Profit Margin
-127.1%
Debt to Equity
11.8
Operating Cash Flow
-$113M
Beta
1.18
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
RYTM Overview
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine RYTM's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important RYTM news, forecast changes, insider trades & much more!
RYTM News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how RYTM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RYTM is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
RYTM is poor value based on its book value relative to its share price (212.18x), compared to the US Biotechnology industry average (4.44x)
P/B vs Industry Valuation
RYTM is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more RYTM due diligence checks available for Premium users.
Valuation
RYTM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-22.49x
Industry
-123.86x
Market
32.47x
RYTM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
212.18x
Industry
4.44x
RYTM is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RYTM's financial health
Profit margin
Revenue
$32.7M
Net Income
-$49.5M
Profit Margin
-155.4%
RYTM's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
RYTM's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$386.7M
Liabilities
$223.6M
Debt to equity
11.8
RYTM's short-term assets ($369.29M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RYTM's short-term assets ($369.29M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RYTM's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
RYTM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$40.4M
Investing
$24.8M
Financing
$32.5M
RYTM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
RYTM vs Biotech Stocks
Rhythm Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.